CLIMB BIO, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CLIMB BIO, INC. (CLYM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.10 million for the 1-month period ending 2026-05-31, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $510.00K.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $216.00K, a 57.65% decline from fiscal 2024.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $510.00K, a 62.94% increase from fiscal 2023.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $313.00K, a 65.79% decline from fiscal 2022.
- CLIMB BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $915.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 1 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2026-05-31 | $1.10M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $216.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $216.00K 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $216.00K 10-Q · filed 2025-08-12 | |||||
| 2024-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $510.00K derived: sum of 2 quarters · filed 2026-03-05 | $510.00K derived: sum of 3 quarters · filed 2026-03-05 | $510.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | $0.00 derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $0.00 derived: sum of 4 quarters · filed 2025-03-25 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $313.00K 10-K · filed 2025-03-25 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $313.00K 10-Q · filed 2024-11-12 | $313.00K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $313.00K 10-Q · filed 2024-08-14 | $313.00K derived: sum of 3 quarters · filed 2024-08-14 | $313.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $313.00K 10-Q · filed 2024-05-15 | $313.00K derived: sum of 2 quarters · filed 2024-05-15 | $313.00K derived: sum of 3 quarters · filed 2024-05-15 | $313.00K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $915.00K 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $915.00K 10-Q · filed 2023-11-14 | $915.00K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $915.00K 10-Q · filed 2023-08-10 | $915.00K derived: sum of 3 quarters · filed 2023-08-10 | $915.00K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $915.00K 10-Q · filed 2023-05-11 | $915.00K derived: sum of 2 quarters · filed 2023-05-11 | $915.00K derived: sum of 3 quarters · filed 2023-05-11 | |||
| 2022-01-01 | $900.00K 10-K · filed 2023-03-06 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |